8-K: Strata Critical Medical Q3 Revenue Jumps 36.7%, Raises 2025 Outlook

Strata Critical Medical reported a 36.7% year-over-year revenue increase to $49.3 million in Q3 2025, driven by strategic acquisitions and organic growth, leading to raised full-year revenue guidance.

Summary

• Revenue for Q3 2025 increased by 36.7% year-over-year to $49.3 million.
• Excluding the Keystone acquisition, revenue grew 29.0% year-over-year.
• Net loss from continuing operations increased to $(9.7) million in Q3 2025, up from $(5.6) million in the prior year period.
• Medical Segment Adjusted EBITDA surged 93.5% to $7.6 million in Q3 2025.
• The company raised its 2025 revenue guidance to $185-195 million, up from $180-190 million, and reaffirmed its Adjusted EBITDA guidance at $13-14 million.
• Operating cash flow was $(37.3) million in Q3 2025, primarily due to $44.3 million in Keystone acquisition consideration paid through payroll.
• Free Cash Flow from continuing operations was $1.9 million, and $2.7 million before aircraft and engine acquisitions.
• Cash and short-term investments stood at $75.9 million at the end of Q3 2025.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, significantly improved profitability in its core medical segment, and raised its full-year revenue guidance. Strategic transactions (divestiture and acquisition) were successfully completed, sharpening the company's focus. While net loss increased due to specific non-operating items and operating cash flow was negative due to acquisition-related payments, the underlying operational performance and future outlook are very positive.

Positives

• Strong revenue growth of 36.7% year-over-year to $49.3 million in Q3 2025.
• Organic revenue growth accelerated to 29.0% in Q3, exceeding mid-teens expectations.
• Medical Segment Adjusted EBITDA increased significantly by 93.5% to $7.6 million.
• Medical Segment Adjusted EBITDA margin excluding Keystone improved to 15.1%.
• Gross profit increased by 75.9% to $9.5 million, with gross margin improving by 440 basis points to 19.4%.
• Flight Profit increased 54.7% to $11.6 million, and Flight Margin improved to 23.6%.
• Successful completion of two transformational transactions: divestiture of the Passenger business and acquisition of Keystone Perfusion.
• Raised 2025 revenue guidance to $185-195 million, indicating strong future expectations.
• Industry-wide Normothermic Regional Perfusion (NRP) adoption rates continued to increase, with transplants of organs that have undergone NRP approximately doubling versus the prior year.
• OrganOx metra received FDA approval for operation during air transport, following a strategic alliance.
• Adjusted Unallocated Corporate Expenses and Software Development decreased to $3.3 million from $3.8 million, driven by cost savings post-divestiture.

Negatives

• Net loss from continuing operations increased by 71.6% to $(9.7) million in Q3 2025 compared to $(5.6) million in the prior year.
• The increase in net loss was primarily driven by a $5.2 million realized loss from sales of short-term investments (Joby Aviation securities) and a legal reserve.
• Operating Cash Flow was negative $(37.3) million in Q3 2025, largely due to $44.3 million of Keystone acquisition consideration paid through payroll.

Risks

• Continued incurrence of significant losses.
• Challenges in realizing anticipated benefits from the divestment of the Passenger business and the acquisition of Keystone Perfusion, including receipt of contingent consideration.
• Potential impact of changes to aircraft ownership.
• Competition from other providers, including those with proprietary organ preservation technology.
• Reliance on contractual relationships with transplant centers, hospitals, and Organ Procurement Organizations, and on certain key customers.
• Risks related to the continuing availability of organ donors and viable donor organs.
• Insufficient reimbursement and funding for organ transport costs.
• Potential for new technology to make ground or commercial air transport of organs more viable, impacting current operations.
• Exposure to negative publicity, reputational damage, litigation, claims, or investigations related to clinical services and perfusion staffing.
• Regulatory changes, legislative reforms, and civil or criminal enforcement actions.
• Difficulties in successfully integrating Keystone and future acquisitions.
• Impact of natural disasters, outbreaks, pandemics, economic, social, weather, geopolitical, and regulatory conditions.
• Adverse publicity from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• Reliance on third-party operators and potential disruptions to their workforce.
• Risks associated with third-party aircraft operators illegally, improperly, or inappropriately operating branded aircraft.
• Vulnerability to system failures, interruptions, or security breaches of information technology systems.
• Challenges in protecting intellectual property rights.
• Fluctuating financial results and the non-comparability of historical financial statements due to discontinued operations.
• Ability to access additional funding to finance operations and manage growth.
• Increases in insurance costs or reductions in insurance coverage.
• Loss of key members of the management team.
• Changes in the fair value of warrants.

Future Outlook

The company raised its 2025 revenue guidance to $185-195 million, reflecting strong performance and strategic initiatives. It reaffirmed its 2025 Adjusted EBITDA guidance at $13-14 million. An Investor Day is scheduled for November 17, 2025, where 2026 guidance and medium-term financial targets will be introduced, signaling continued focus on growth and value creation in the critical medical logistics sector.

Management Comments

• "We closed two transformational transactions during the quarter, the divestiture of our Passenger business and the acquisition of Keystone Perfusion, setting us up incredibly well for long term growth and value creation." Melissa Tomkiel, Co-CEO and General Counsel.
• "Organic revenue growth accelerated to 29.0% in Q3, well above our expectation for mid-teens revenue growth in the second half of the year, resulting in record Adjusted EBITDA performance." Melissa Tomkiel, Co-CEO and General Counsel.
• "Our sequential growth in Q3 2025 versus Q2 2025 is particularly impressive in the backdrop of the seasonal sequential decline in industry transplant volumes, demonstrating Strata's continued market share gains and our customers' adoption of new services." Melissa Tomkiel, Co-CEO and General Counsel.
• "Our integration of Keystone is off to a fantastic start." Will Heyburn, Co-CEO and CFO.
• "The team is focused on tailoring solutions that deliver operational efficiencies and cost savings to the transplant community broadly, starting with our existing customers." Will Heyburn, Co-CEO and CFO.
• "Industry-wide NRP adoption rates continued to increase during Q3 with transplants of organs that have undergone NRP approximately doubling versus the prior year. This is an encouraging validation of our strategy to increase exposure to the fastest growing sectors of the transplant ecosystem, and further aligns our mission with those of our customers which is to enable more reliable and lower-cost access to life-saving donor organs." Will Heyburn, Co-CEO and CFO.

Industry Context

Strata Critical Medical operates in the specialized and growing U.S. healthcare logistics and medical services industry, particularly focused on organ transplant. The increasing adoption of Normothermic Regional Perfusion (NRP) technology, with transplants of organs undergoing NRP approximately doubling year-over-year, indicates a significant industry trend towards advanced organ preservation and transport methods. Strata's strategic acquisition of Keystone Perfusion and alliance with OrganOx positions it to capitalize on these trends, offering an integrated 'one call solution' for donor organ recovery and critical medical transport, aligning with the broader industry's need for more reliable and cost-effective access to life-saving donor organs.

Comparison to Industry Standards

• The significant year-over-year revenue growth of 36.7% (29.0% organic) suggests strong market penetration and demand for Strata's specialized medical logistics and perfusion services, potentially outperforming general healthcare logistics market growth.
• The substantial increase in Medical Segment Adjusted EBITDA (93.5%) and margin improvement (450bps) indicates effective integration of new services and operational efficiencies, which is a positive sign in a capital-intensive and highly regulated industry.
• The doubling of NRP adoption rates for organ transplants versus the prior year highlights Strata's strategic alignment with a rapidly expanding and technologically advanced segment of the transplant ecosystem, potentially positioning it ahead of competitors relying on traditional methods.
• The successful divestiture of the non-core Passenger business and acquisition of Keystone Perfusion demonstrates a clear strategic focus on the high-growth critical medical sector, a move often seen in companies aiming to optimize their portfolio for specialized market leadership.

Legal Proceedings

• Legal expenses and regulatory advocacy fees of $5.045 million in Q3 2025, primarily related to the Drulias lawsuit.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved core profitability, raised guidance, and strategic focus. Potential for increased shareholder value.
• Employees: Integration of Keystone Perfusion may lead to new opportunities or restructuring. Employees participating in the "phantom equity" plan received acquisition consideration through payroll.
• Customers: Benefit from tailored solutions delivering operational efficiencies and cost savings, and continued market share gains in critical medical services. Increased adoption of new services.
• Suppliers: Continued demand for aircraft, vehicles, medical devices, and disposable medical products due to growth in Air Logistics, Ground Logistics, and Organ Placement Services.
• Creditors: Improved financial health and strategic positioning may enhance creditworthiness, though increased net loss and negative operating cash flow in the short term could be noted.

Next Steps

• Introduce 2026 guidance and medium-term financial targets at the Investor Day on November 17, 2025.
• Continue integration of Keystone Perfusion to deliver operational efficiencies and cost savings to the transplant community.
• Further increase exposure to the fastest growing sectors of the transplant ecosystem, such as NRP.

Key Dates

Recommendation

The company demonstrated exceptional operational performance in Q3 2025, with significant year-over-year revenue growth (36.7% overall, 29.0% organic) and a near-doubling of Medical Segment Adjusted EBITDA. The successful divestiture of the non-core Passenger business and the strategic acquisition of Keystone Perfusion have sharpened the company's focus on the high-growth critical medical logistics sector, positioning it well for future expansion, particularly with the increasing adoption of NRP technology. The raised 2025 revenue guidance further underscores management's confidence. While a higher net loss and negative operating cash flow were reported, these are largely attributable to one-time items (realized loss on short-term investments from the divestiture and acquisition-related payments) rather than core operational weakness. The upcoming Investor Day to introduce 2026 guidance and medium-term targets suggests a clear growth trajectory. These factors collectively indicate a strong investment opportunity.

Keywords

Medical Logistics, Organ Transplant, Healthcare Services, Critical Medical Transport, Perfusion Services, Organ Recovery, Adjusted EBITDA, Revenue Growth, Keystone Perfusion, Joby Aviation, FDA Approval, NRP Adoption, Financial Results, Q3 2025 Earnings